BTIG analyst Thomas Shrader initiated coverage of Invivyd (IVVD) with a Buy rating and $10 price target The company has a proven track record of producing effective antibodies, the analyst tells investors in a research note. The firm believes Invivyd’s VYD2311 offers a “much larger” total addressable market relative to Pemgarda. This is why BTIG recommends buying the stock.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD: